Literature DB >> 16195551

Expression of human peripheral cannabinoid receptor for structural studies.

Alexei A Yeliseev1, Karen K Wong, Olivier Soubias, Klaus Gawrisch.   

Abstract

Human peripheral-type cannabinoid receptor (CB2) was expressed in Escherichia coli as a fusion with the maltose-binding protein, thioredoxin, and a deca-histidine tag. Functional activity and structural integrity of the receptor in bacterial protoplast membranes was confirmed by extensive binding studies with a variety of natural and synthetic cannabinoid ligands. E. coli membranes expressing CB2 also activated cognate G-proteins in an in vitro coupled assay. Detergent-solubilized receptor was purified to 80%-90% homogeneity by affinity chromatography followed by ion-exchange chromatography. By high-resolution NMR on the receptor in DPC micelles, it was determined that purified CB2 forms 1:1 complexes with the ligands CP-55,940 and anandamide. The receptor was successfully reconstituted into phosphatidylcholine bilayers and the membranes were deposited into a porous substrate as tubular lipid bilayers for structural studies by NMR and scattering techniques.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16195551      PMCID: PMC2253291          DOI: 10.1110/ps.051550305

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  27 in total

1.  Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630.

Authors:  R A Ross; H C Brockie; L A Stevenson; V L Murphy; F Templeton; A Makriyannis; R G Pertwee
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

2.  Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists.

Authors:  R Lan; Q Liu; P Fan; S Lin; S R Fernando; D McCallion; R Pertwee; A Makriyannis
Journal:  J Med Chem       Date:  1999-02-25       Impact factor: 7.446

3.  Quantitative evaluation of neurotensin receptor purification by immobilized metal affinity chromatography.

Authors:  R Grisshammer; J Tucker
Journal:  Protein Expr Purif       Date:  1997-10       Impact factor: 1.650

Review 4.  Molecular aspects of cannabinoid receptors.

Authors:  L A Matsuda
Journal:  Crit Rev Neurobiol       Date:  1997

5.  Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors.

Authors:  M Glass; J K Northup
Journal:  Mol Pharmacol       Date:  1999-12       Impact factor: 4.436

6.  Membrane protein-ligand interactions in Escherichia coli vesicles and living cells monitored via a biosynthetically incorporated tryptophan analogue.

Authors:  J Broos; F ter Veld; G T Robillard
Journal:  Biochemistry       Date:  1999-08-03       Impact factor: 3.162

7.  Purification and characterization of the human adenosine A(2a) receptor functionally expressed in Escherichia coli.

Authors:  H Markus Weiss; Reinhard Grisshammer
Journal:  Eur J Biochem       Date:  2002-01

8.  The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor.

Authors:  C N Chin; J W Murphy; J W Huffman; D A Kendall
Journal:  J Pharmacol Exp Ther       Date:  1999-11       Impact factor: 4.030

Review 9.  Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development.

Authors:  R G Pertwee
Journal:  Expert Opin Investig Drugs       Date:  2000-07       Impact factor: 6.206

Review 10.  Pharmacology of cannabinoid receptor ligands.

Authors:  R G Pertwee
Journal:  Curr Med Chem       Date:  1999-08       Impact factor: 4.530

View more
  40 in total

1.  Mistic and TarCF as fusion protein partners for functional expression of the cannabinoid receptor 2 in Escherichia coli.

Authors:  Ananda Chowdhury; Rentian Feng; Qin Tong; Yuxun Zhang; Xiang-Qun Xie
Journal:  Protein Expr Purif       Date:  2012-03-03       Impact factor: 1.650

2.  Global fold of human cannabinoid type 2 receptor probed by solid-state 13C-, 15N-MAS NMR and molecular dynamics simulations.

Authors:  Tomohiro Kimura; Krishna Vukoti; Diane L Lynch; Dow P Hurst; Alan Grossfield; Michael C Pitman; Patricia H Reggio; Alexei A Yeliseev; Klaus Gawrisch
Journal:  Proteins       Date:  2013-10-17

3.  Use of dual affinity tags for expression and purification of functional peripheral cannabinoid receptor.

Authors:  Alexei Yeliseev; Lioudmila Zoubak; Klaus Gawrisch
Journal:  Protein Expr Purif       Date:  2006-12-12       Impact factor: 1.650

4.  Recombinant Expression and Purification of Cannabinoid Receptor CB2, a G Protein-Coupled Receptor.

Authors:  Alexei A Yeliseev
Journal:  Methods Mol Biol       Date:  2021

5.  Expression and Preparation of a G-Protein-Coupled Cannabinoid Receptor CB2 for NMR Structural Studies.

Authors:  Alexei Yeliseev
Journal:  Curr Protoc Protein Sci       Date:  2019-01-09

6.  Probing thermostability of detergent-solubilized CB2 receptor by parallel G protein-activation and ligand-binding assays.

Authors:  Ryan L Beckner; Lioudmila Zoubak; Kirk G Hines; Klaus Gawrisch; Alexei A Yeliseev
Journal:  J Biol Chem       Date:  2019-11-27       Impact factor: 5.157

7.  Expression and NMR Structural Studies of Isotopically Labeled Cannabinoid Receptor Type II.

Authors:  Alexei Yeliseev; Klaus Gawrisch
Journal:  Methods Enzymol       Date:  2017-07-11       Impact factor: 1.600

8.  Bacterially expressed human serotonin receptor 3A is functionally reconstituted in proteoliposomes.

Authors:  Jung-Hyun Na; Jaeil Shin; Yuna Jung; Dongbin Lim; Yeon-Kyun Shin; Yeon Gyu Yu
Journal:  Protein Expr Purif       Date:  2013-01-12       Impact factor: 1.650

9.  Surface plasmon resonance applied to G protein-coupled receptors.

Authors:  Silvia Locatelli-Hoops; Alexei A Yeliseev; Klaus Gawrisch; Inna Gorshkova
Journal:  Biomed Spectrosc Imaging       Date:  2013-07-01

10.  High-throughput T7 LIC vector for introducing C-terminal poly-histidine tags with variable lengths without extra sequences.

Authors:  Jonas Lee; Sung-Hou Kim
Journal:  Protein Expr Purif       Date:  2008-09-14       Impact factor: 1.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.